Biotie to acquire neurology and immunology focussed pharmaceutical company elbion GmbH
"Bringing together the outstanding pharmaceutical development capabilities and strong clinical pipelines of both companies will create a European leader in the CNS and inflammation market," says Mr. Juha Jouhki, the Chairman of Biotie. Mr Luc Philips, the Chairman of elbion NV stated that "this business combination is a unique opportunity to combine complementary programs and capabilities with sufficient financial means to reach key value inflection points".
The current CEO of Biotie Timo Veromaa will continue as the CEO of the new entity. Elbion's CEO, Bernd Kastler will join the Board of Biotie, along with current elbion Board members Ann Hanham and Christoph Schröder. The company will operate out of its two locations in Turku, Finland and Radebeul, Germany.
The transaction is subject to shareholder approval of both companies and is expected to close on 14 November 2008.
Most read news
Topics
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.